• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane

tetano

Editor, Senior Moderator
Eur J Clin Microbiol Infect Dis. 2018 Apr 6. doi: 10.1007/s10096-018-3241-7. [Epub ahead of print]
[h=1]Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation.[/h] Rodriguez-Goncer I[SUP]1[/SUP], Thomas S[SUP]2[/SUP], Foden P[SUP]3[/SUP], Richardson MD[SUP]4,[/SUP][SUP]5[/SUP], Ashworth A[SUP]6[/SUP], Barker J[SUP]6[/SUP], Geraghty CG[SUP]7[/SUP], Muldoon EG[SUP]8,[/SUP][SUP]9,[/SUP][SUP]10[/SUP], Felton TW[SUP]11,[/SUP][SUP]12,[/SUP][SUP]13[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] To identify the incidence, risk factors and impact on long-term survival of invasive pulmonary aspergillosis (IPA) and Aspergillus colonisation in patients receiving vv-extracorporeal membrane oxygenation (ECMO). A retrospective evaluation was performed of patients receiving vv-ECMO at a tertiary hospital in Manchester (UK) between January 2012 and December 2016. Data collected included epidemiological data, microbiological cultures, radiographic findings and outcomes. Cases were classified as proven IPA, putative IPA or Aspergillus colonisation according to a validated clinical algorithm. One hundred thirty-four patients were supported with vv-ECMO, median age of 45.5 years (range 16.4-73.4). Ten (7%) patients had putative IPA and nine (7%) had Aspergillus colonisation. Half of the patients with putative IPA lacked classical host risk factors for IPA. The median number of days on ECMO prior to Aspergillus isolation was 5 days. Immunosuppression and influenza A infection were significantly associated with developing IPA in a logistic regression model. Cox regression model demonstrates a three times greater hazard of death associated with IPA. Overall 6-month mortality rate was 38%. Patients with putative IPA and colonised patients had a 6-month mortality rate of 80 and 11%, respectively. Immunosuppression and influenza A infection are independent risk factors for IPA. IPA, but not Aspergillus colonisation, is associated with high long-term mortality in patients supported with vv-ECMO.


[h=4]KEYWORDS:[/h] Aspergillus fumigatus; ECMO; Galactomannan; Outcome; Voriconazole

PMID: 29623451 DOI: 10.1007/s10096-018-3241-7
 
Back
Top Bottom